ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Savara Inc. (SVRA) The shareholder class action lawsuit filed against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts regarding Savara’s biologics license application for MOLBREEVI between March 7, 2024 and May 2 ...

ATLANTA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (i) DexCom had made material design changes to the G6 and G7 unauthorized by the United States Food and Drug Administration (the "FDA"); (ii) the foregoing design changes rendered the ...

Unicycive Therapeutics (UNCY) 集体诉讼 - 诉讼指控公司在2024年3月29日至2025年6月27日期间就满足FDA生产合规要求的能力做出 materially false and/or misleading statements [1] - 诉讼涉及公司未能披露有关其满足FDA生产合规要求的 material facts [1] - 寻求任命首席原告的截止日期为2025年10月14日 [2] KinderCare Learning Companies (KLC) 集体诉讼 - 诉讼指控公司在2024年10月IPO相关的Registration Statement中就其设施提供的护理质量做出 materially false and/or misleading statements [2] - 诉讼涉及公司未能披露有关其设施护理质量的 material facts [2] - 寻求任命首席原告的截止日期为2025年10月14日 [3]

诉讼核心指控 - 公司被指控未能向投资者披露其向自身出售场外金融工具[1] - 公司被指控在子公司与关联方之间的财务报告中存在不一致，涉及公司间应收款和贷款[1] - 由于上述问题，公司的财务报表被认为不可信赖[1] - 因此，公司管理层关于其业务、运营和前景的正面陈述被指控为存在重大误导性或缺乏合理依据[1] 诉讼程序信息 - 该股东集体诉讼针对Marex公司提起，由Holzer & Holzer, LLC律师事务所代表在2024年5月16日至2025年8月5日期间购买该公司股票并遭受重大损失的投资者发起[1][2] - 申请担任此案首席原告的法院截止日期为2025年12月8日[3]

ATLANTA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cepton, Inc. (“Cepton” or the “Company”) (NASDAQ: CPTN). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Spirit’s business, operations, and prospects, including allegations that: (i) Cepton had received a credible third-party bid valuing Cepton at more than double the Koito Acquisition; (ii) Cepton's Board ...

ATLANTA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Spirit Aviation Holdings, Inc. (“Spirit” or the “Company”) (NYSE: FLYY). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Spirit’s business, operations, and prospects, including allegations that: (i) Spirit was at substantial risk of being unable to meet certain of its debt and other financial obligations; ...

集体诉讼核心指控 - 股东对KBR公司提起了集体诉讼，指控公司方做出了重大虚假和/或误导性陈述，和/或未能披露重大不利信息 [1] - 诉讼涉及KBR的业务、运营和前景，具体指控称尽管公司已知美国国防部运输司令部（TRANSCOM）对HomeSafe履行全球家居用品合同的能力存在重大担忧，但公司方仍声称合作伙伴关系没有问题，并将在未来几个季度加速发展 [1] - 诉讼涉及的股东购买KBR股票的时间段为2025年5月6日至2025年6月19日 [1] 法律程序与律所信息 - 向法院申请担任本案首席原告的截止日期为2025年11月18日 [2] - 代理此案的Holzer & Holzer, LLC律所在2021、2022和2023年被ISS评为顶级证券诉讼律所，自2000年成立以来，该所律师在为因欺诈和其他公司不当行为而受害的股东追回数亿美元方面发挥了关键作用 [2]

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Jasper’s business, operations, and compliance policies, including allegations that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on ...

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Quanex Building Products Corporation (“Quanex” or the “Company”) (NYSE: NX). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Quanex’s business, operations, and prospects, including allegations that: (1) the Company’s procedures and policies regarding tooling and equipment maintenance in its Tyman, Mexico ...

ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). The lawsuit alleges Defendants represented that Cytokinetics expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Miti ...